Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Navin Varadarajan of the University of Houston, Kelly Pracht of nVenue, and Atul Varadhachary of Fannin. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes two health tech innovators and a sportstech CEO.

Kelly Pracht, CEO and co-founder of nVenue

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.” Read more.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Navin Varadarajan, M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via UH

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.” Read more.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

UH and a local company are developing a new COVID-19 vaccine. Photo by Getty Images

University of Houston partners with local company to develop cutting-edge COVID vaccine

COOGS TACKLE COVID

A major Houston university has taken a big leap in the race to battle debilitating diseases such as COVID-19. The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston-based biotech company developing novel vaccines against aggressive respiratory diseases such as coronavirus, according to a press release.

This means AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering. Varadarajan is a co-founder of AuraVax.

The vaccine is a nasal inhalant, much like FluMist. Based on pre-clinical experimentation, Varadarajan reports his technology not only elicits a mucosal immune response, but also systemic immunity, according to UH.

"We plan to stop COVID-19, a respiratory virus, at its point of entry — the nasal cavity — and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to COVID-19," said Varadarajan in a statement.

So how does it work? Varadarajan is utilizing the spike protein, which helps the virus enter the target cell, and is the major target for neutralizing antibodies as it binds to the ACE 2 cellular receptor, for virus entry. The professor prefers using proteins because of their ability to induce strong immune responses, flexibility and scalability, and the absence of infectious particles, per UH.

Varadarajan's company, AuraVax, has created a next-generation vaccine platform that combines the potential of in-home administration with the ability to deliver complete immunity. The technology has been validated for COVID-19 in initial animal studies and results in immunity measured by both B-cell and T-cell responses.

"We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution," said Varadarajan. "We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine technology to address a multitude of respiratory viruses, starting with COVID-19."

------

This article originally ran on CultureMap.

The University of Houston, a Tier One research institution, has a few ongoing projects focusing on treating or preventing COVID-19. Photo courtesy of University of Houston

University of Houston researchers studying COVID-19 prevention and treatment

research roundup

Researchers across the country are focusing on all things COVID-19 — from biotherapies and treatment to vaccines and prevention. A handful of researchers based out of the University of Houston are doing their best to move the needle on a cure or reliable vaccine.

Here are three research projects currently ongoing at UH.

UH pharmacy professors take it back to basics

UH College of Pharmacy professors Gomika Udugamasooriya (left) and Bin Guo are studying how the virus enters the human body. Photo via uh.edu

When thinking about how to prevent the spread of COVID-19, two UH pharmacy professors are looking at how the virus enters the body. Then, this information can help develop protection of that entry point.

"The human entry of coronaviruses depends on first binding of the viral spike proteins to human cellular receptors that basically offer a cellular doorknob," says Gomika Udugamasooriya, associate professor of pharmacological and pharmaceutical sciences, in a press release. "The virus latches onto the specific human cellular receptor, ACE2, and sneaks inside to replicate itself within the cell to spread throughout the body."

Now, the goal of new drugs and vaccines is to protect that ACE2. Udugamasooriya is working with Bin Guo, associate professor of pharmaceutics, on this research, which is in the initial screening levels and identified drug-lead validations. They are working to apply their unique cell-screening technology to identify specific synthetic chemical drug leads called peptoids that can bind to ACE2 receptor, according to the release.

"Peptoids are easier to make, compatible with biological systems and economical to produce," says Udugamasooriya.

Duo aims to create inhalation vaccine for COVID-19

Navin Varadarajan, UH engineering professor (left), and pharmaceutics professor Xinli Liu, pharmaceutics professor, are collaborating on development and testing of a COVID-19 inhalation vaccine. Photo via uh.edu

If the disease itself is airborne, can't the vaccine be too? That's what M.D. Anderson Associate Professor of Chemical and Biomolecular Engineering Navin Varadarajan looking into.

"For airborne pathogens, the nasal mucosa is the first point of defense that needs to be breached," says Varadarajan in a news release. "Mucosal immunity and vaccines are fundamentally important for a wide range of pathogens including influenza, severe acute respiratory syndrome coronavirus (SARS-CoV) and the current SARS-CoV-2."

Varadarajan is focusing on the spike protein to protect at virus entry. These proteins are known for building strong immune responses, flexibility and scalability, and absence of infectious particles. He is working with Xinli Liu, associate professor of pharmaceutics.

"As with any vaccine, a variety of factors determine their efficacy including the antigen used for electing a response, the adjuvants and immunomodulators, the efficient delivery of the antigen to appropriate target cells, and the route of vaccination," Varadarajan says.

The man with three different vaccine options

UH Professor Shaun Zhang is in the process of developing three COVID-19 vaccine candidates for injection. Photo via uh.edu

Shaun Zhang, director for the Center for Nuclear Receptors and Cell Signaling, usually works on developing treatment or vaccines for cancer and viral infection. Now, he's switched gears to work on three different vaccine candidates for COVID-19.

"The data collected from our studies show that our vaccine candidates can generate neutralizing antibodies, which can protect cells from infection by SARS-CoV-2 when tested in vitro," says Zhang in a press release. "We are now working on further improvement for the vaccine design."

Zhang's approach is neutralizing antibody production, and he's tapped into using "subunit vaccine containing either the entire spike protein or the receptor binding portion, which helps the virus enter the target cell, and delivered either by DNA formulation or by a herpes simplex virus-based vector," according to the release. Low cost and simplicity are two priorities for Zhang's work.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

New downtown Houston hub opens to support energy transition innovators

now open

Three Houston energy innovators have cut the ribbon on a new space for energy transition innovation.

The Energy Tech Nexus, located in the historic Niels Esperson Building at the corner of Travis and Rusk Avenue, opened on September 10, which was proclaimed Energy Tech Nexus Day by the city.

Jason Ethier and Juliana Garaizar, formerly in leadership roles at Greentown Labs, teamed up with Nada Ahmed, previously headed innovation and transformation at Aker Solutions, launched ETN as a community for energy transition startups. The new hub plans to host incubation programs, provide mentorship, and open doors to funding and strategic partnerships for its members.

"We are creating more than a space for innovation," Garaizar, who serves as CEO of ETN, says in a news release. "We are crafting a community where pioneers in technology and energy converge to challenge the status quo and accelerate the shift to sustainable energy solutions."

The hub describes its goal of tackling the "trilemma" of energy security, sustainability, and affordability while also contributing to the mission of setting up Houston as the global center for energy transition. To accomplish that mission, ETN will help facilitate rapid deployment of cutting-edge energy technologies.

'The future of energy is not just being written here in Houston; it's being rewritten in more sustainable, efficient, and innovative ways," adds Garaizar. "Houston provides the perfect backdrop for this transformation, offering a rich history in energy and a forward-looking approach to its challenges and opportunities."

"We believe that a broad spectrum of perspectives is crucial in solving global energy challenges. It's about bringing everyone to the table — startups, industry leaders, and investors from all backgrounds," she continues.

Ethier, who co-hosts the Energy Tech Startups Podcast with Ahmed, says he hopes that ETN acts as a meeting place for energy transition innovators.

"By providing the right tools, access, and expertise, we are enabling these companies to leap from ideation to implementation at an unprecedented pace;" Ethier explains. "The interaction between startups and established companies within Energy Tech Nexus creates a unique synergy, fostering innovations that might otherwise take years to mature in isolation."

Payal Patel, an angel investor who has held leadership roles at Station Houston, Plug and Play Ventures, and Softeq, also contributed to launching ETN, which is collaborating with George Liu, who has over 15 years of investment banking experience across energy, cleantech and hardtech with more than $20 billion in M&A projects across his career.

In May, ETN teamed up with Impact Hub Houston to establish the Equitable Energy Transition Alliance and Lab to accelerate startup pilots for underserved communities. The initiative announced that it's won the 2024 U.S. Small Business Administration Growth Accelerator Fund Competition, or GAFC, Stage One award.

ETN celebrated its opening during the inaugural Houston Energy and Climate Week.

------

This article originally ran on EnergyCapital.

Houston innovator breaks down industry silos with new bp, NASA partnership

houston innovators podcast episode 252

The recently announced partnership between bp and NASA is a match made in Houston. The energy giant, which as its United States headquarters in Houston, entered into a Space Act Agreement with NASA to combine resources and efforts with innovation in mind.

"Houston has always been known as the Space City, and we're also known as the Energy Capital of the World, but there hasn't always been collaboration," Ken Nguyen, principal technical program manager at bp, says on the Houston Innovators Podcast. "The challenges that NASA is facing is very similar to the challenges that the oil industry faces — we operate in very harsh environments, safety is the most critical aspect of our operation, and now the economic business model for NASA has changed."

Nguyen explains that while both bp and NASA are navigating similar challenges and changes within their industry, they are going about it in different ways. That's where the opportunity to collaborate comes in.

The partnership, which is still new and not fully fleshed out, will look at collaborative innovation into a few focus areas to start out with, including hydrogen storage and development, AI and general intelligence, robotics, and remote operations

"Houston continues to excel — in energy production and in space exploration — but by coming together," Nguyen says, "and for us to be able to tap into (NASA's) knowledge is tremendous. And we, within oil and gas, have a unique set of skills to blend into that with the hopes being that the city becomes this incubator for technology. The potential is there."

Nguyen oversees the implementation of new technologies at bp, and that includes software and hardtech, from cybersecurity to the digitization of the industry, which is an integral part of bp's energy transition plan, Nguyen says on the show.

"For bp, we do feel like as we transition as an international oil and gas company into an integrated energy company and we lean into the energy transition, the adoption of new technology is a critical part of making that viable for the planet and for the company," he says.

According to Nguyen, bp has invested its resources into exploring energy transition technologies like electric vehicle charging — including opening a fast-charging station at its Houston office — and renewable energy, including a solar farm about 10 miles northeast of Corpus Christi.

Another technology bp is keen on is digital twin technology, which can be crucial for enhancing safety for bp personnel and reducing emissions.

Nguyen says digital twin technology "allows us to be able to design and mirror scenarios with real-time variables, such as weather, off-take demands, and volatility."

Deadline extended: Nominations launch, tickets open for annual Houston Innovation Awards

call for submissions

Update: The nomination deadline has been extended until September 16.

Calling all Houston innovators — InnovationMap needs your help identifying the best and brightest in the Houston innovation ecosystem.

For the fourth year, InnovationMap is hosting its signature awards program that will recognize the top startups and innovators in Houston. The awards program will be on Thursday, November 14, at the Texas Medical Center's Helix Park. Tickets and tables are on sale now.

The nomination period — which includes submitting nominations on behalf of yourself or others — will close September 10. Nominees will be sent an application, which will be due September 23. A panel of judges will review the applications and finalists will be announced and notified ahead of the event.

This year's categories include a few new awards — as well as the return of some crowd favorites. Nominees can be submitted to multiple categories. The 2024 Houston Innovation Awards include:

  • Minority-founded business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation
  • Female-founded business, honoring an innovative startup founded or co-founded by a woman
  • Energy transition business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond
  • Health tech business, honoring an innovative startup within the health and medical technology
  • Deep tech business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges
  • AI/data science business, honoring an innovative startup utilizing artificial intelligence and data science within a tech solution
  • Scaleup of the year, honoring an innovative later stage startup that's recently reached a significant milestone in company growth
  • Community champion organization, honoring a corporation, nonprofit, university, or other organization that plays a major role in the Houston innovation community
  • People’s choice: Startup of the Year, a startup celebrating a recent milestone or success and the winner will be selected by the community via online portal and announced at the event
  • Ecosystem builder, honoring an individual who has acted as a leader in developing Houston’s startup ecosystem
  • Investor of the year, honoring an individual who is leading venture capital or angel investing
  • Mentor of the year, honoring an individual who dedicates their time and expertise to guide and support to budding entrepreneurs

Additionally, the awards gala will honor an innovator who's made a lasting impact on the Houston innovation community. While you may nominate an individual for the Trailblazer Award via the online form, the judging committee will not require applications or nominations for this category and will be considering potential honorees from the ecosystem at large.

If you are interested in sponsorship opportunities, including the opportunity to sponsor any of the above award categories, please reach out to sales@innovationmap.com.

Click here to submit a nomination or see form below.


View All Listings